Most babies born to mothers who used opioids during pregnancy are delivered with a form of addiction called neonatal abstinence syndrome. It is treated in the hospital, but how long the treatment lasts depends on the severity of withdrawal symptoms called neonatal opioid withdrawal syndrome — the amount of distress that the newborn is experiencing.
The “Eat, Sleep, Console” approach for newborns with neonatal opioid withdrawal syndrome reduced average time in the hospital by 45% compared to usual care, which typically includes morphine, according to a randomized controlled study at 26 sites across the United States.
It was not a direct comparison but, rather, an analysis of time to discharge yielded by a standard withdrawal severity assessment tool, which the authors said may overestimate the need for pharmacologic treatment compared with this relatively new approach.
Although it was developed in 2014 and has experienced increasing use in recent years, whether it “can safely reduce the time until infants are medically ready for discharge when it is applied broadly across diverse sites is unknown," the authors wrote in the background section of the research article published June 22 in the New England Journal of Medicine.
“The Eat, Sleep, Console Care Tool relies on a function-based assessment of withdrawal severity that is focused on an infant’s ability to eat, sleep and be consoled, along with the use of nonpharmacologic interventions (e.g., low-stimulation environment, skin-to-skin contact, clustered care, and breast-feeding) as the first line of treatment and empowerment of families and caregivers in the care of their infants,” wrote first and corresponding author Leslie W. Young, M.D., a neonatologist and associate professor at the University of Vermont Larner College of Medicine in Burlington, and more than 40 co-authors for the ACT NOW collaborative.
Neonatal opioid withdrawal syndrome refers to a set of symptoms that appear at or soon after birth. They include body shakes (tremors), excessive crying and fussiness, fever, diarrhea, seizures, trouble sleeping, poor feeding and breathing problems.
They are caused by neonatal abstinence syndrome (NAS),which is caused by prenatal exposure to opioids, often in the form of medications used to treat the mother’s addiction during pregnancy. NAS is diagnosed every 18 minutes in the U.S.
NAS is successfully treated soon after birth, although infants experience extreme but temporary distress during withdrawal. But it results in none of the serious lifelong disabilities common to fetal alcohol syndrome.
For this study, Young and her colleagues enrolled 1,305 infants. They found that the number of days from birth until readiness for hospital discharge was 8.2 in the Eat, Sleep, Console group and 14.9 in the usual care group, a difference of 45%. Adverse outcomes were similar.
Related: Study Finds No Adverse Outcomes in Newborns of Mothers Treated with Opioids Postpartum
“The Eat, Sleep, Console approach” to babies born addicted to opioids, concludes an accompanying editorial by Wanda D. Barfield, M.D., M.P.H., director of the CDC Division of Reproductive Health, “offers an innovative opportunity to use a tried-and-true way to care for babies affected by neonatal opioid withdrawal syndrome — by holding them.”
Preterm infant mortality in the U.S. has dropped, but remains high for Black infants
September 6th 2023The mortality rate has dropped for Black premature infants, but they are still 1.4 times more likely to die than White premature infants, according to findings reported in JAMA Pediatrics today.
Read More
Warning Letters Were Issued to Infant Formula Manufacturers by the FDA For Violations
September 5th 2023Warning letters were issued to infant formula manufacturers ByHeart Inc., Mead Johnson Nutrition (Reckitt), and Perrigo Wisconsin LLC for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the federal agency stated in a press release.
Read More
FDA Approves First RSV Vaccine for Pregnant Women to Protect Infants
August 24th 2023Monday’s action followed by one month the agency’s approval of another first — a monoclonal antibody immunization for newborns — against respiratory syncytial virus, the leading cause of infant hospitalizations in the United States
Read More